Oral Presentation Australian & New Zealand Obesity Society 2016 Annual Scientific Meeting

Invited talk: The role of NAFLD and Hepatokines in Metabolism (#20)

Norbert Stefan 1 2 3
  1. Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich , University of Tübingen, Tübingen, Germany
  2. German Center for Diabetes Research (DZD, Tübingen, Germany
  3. University Hospital of Tübingen, Tübingen, BW, Germany

The liver is known to be involved in the natural history of the ongoing epidemics of type 2 diabetes mellitus and cardiovascular disease. In particular, the liver has a role in increased glucose production and dysregulated lipoprotein metabolism, conditions that are often found in patients with nonalcoholic fatty liver disease. Additionally, several proteins that are exclusively or predominantly secreted from the liver are now known to directly affect glucose and lipid metabolism. In analogy to the functional proteins released from adipose tissue and skeletal muscle-adipokines and myokines-these liver-derived proteins are known as hepatokines. The first hepatokine that has been proven to have a major pathogenetic role in metabolic diseases is α2-HS-glycoprotein (fetuin-A). Production of this glycoprotein is increased in steatotic and inflamed liver, but not in expanded and dysregulated adipose tissue. Thus, research into this molecule and other hepatokines is expected to aid in differentiating between the contribution of liver and those of skeletal muscle and adipose tissue, to the pathogenesis of type 2 diabetes mellitus and cardiovascular disease.